Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.68 |
| ▸ | CDK4 | P11802 | 9/20 | 0.68 |
| ▸ | AURKA | O14965 | 9/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.68 |
| ▸ | CDK9 | P50750 | 10/20 | 0.66 |
| ▸ | CDK1 | P06493 | 4/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.66 |
| ▸ | JAK2 | O60674 | 4/20 | 0.66 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.66 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.66 |
| ▸ | PLK4 | O00444 | 3/20 | 0.66 |
| ▸ | WEE1 | P30291 | 3/20 | 0.66 |
| ▸ | FLT3 | P36888 | 3/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.66 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.66 |
| ▸ | PAK4 | O96013 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | FYN | P06241 | 2/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175394 | 0.92 | CDK2 (0.67) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4161877 | 0.87 | CDK2 (0.67) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4161825 | 0.84 | CDK2 (0.72) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4164435 | 0.83 | CDK2 (0.54) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2073867 | 0.81 | CDK2 (1.00) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2076109 | 0.81 | CDK2 (0.84) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL2076215 | 0.80 | CDK2 (0.68) | CDK2CDK4AURKAAURKBCDK9 | |
| Cyc-116 SCHEMBL29366353 | 0.80 | CDK2 (1.00) | CDK2CDK4AURKAAURKBCDK9 | |
| Cyc-116 SCHEMBL2074998 | 0.80 | CDK2 (1.00) | CDK2CDK4AURKAAURKBCDK9 | |
| SCHEMBL4798825 | 0.79 | CDK2 (0.74) | CDK2CDK4AURKAAURKBCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | CDK2 1/4885CDK4 2/4885AURKA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.